symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
NEXI,0.221,2.116938,82662,5763349,0,0.15-0.814,0.016,"NexImmune, Inc.",USD,0001538210,US65344D1090,65344D109,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.neximmune.com,"NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.",Ms. Kristi  Jones R.Ph.,Healthcare,US,50,301 825 9810,9119 Gaither Road,Gaithersburg,MD,20877,,0,https://financialmodelingprep.com/image-stock/NEXI.png,2021-02-12,False,False,True,False,False
